⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OVID News
Ovid Therapeutics Inc. Common Stock
Form 8-K
sec.gov
OVID
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
globenewswire.com
OVID
Form 8-K
sec.gov
OVID
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
OVID
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
globenewswire.com
OVID
Ovid Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
OVID
Longwood Healthcare Leaders to Host Senior Pharma and Biotech Leaders at Annual Leadership Summit, Miami CEO
accessnewswire.com
BLCO
PFE
LLY
CSL
GSK
INCY
JNJ
OVID
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
globenewswire.com
OVID
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
globenewswire.com
OVID
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
globenewswire.com
OVID